Currently out of the existing stock ratings of Matt Miksic, 362 are a BUY (74.64%), 96 are a HOLD (19.79%), 27 are a SELL (5.57%).
Analyst Matt Miksic, currently employed at BARCLAYS, has had 53.16% of price targets met with an average potential upside of 20.48%, reached in 278 days on average.
Matt Miksic has documented 975 price targets and ratings displayed on 35 stocks. The coverage is on Healthcare, Communication Services sectors.
Most recent stock forecast was given on ABT, Abbott Laboratories at 07-Oct-2026.
Analyst best performing recommendations are on HSIC (HENRY SCHEIN).
The best stock recommendation documented was for ISRG (INTUITIVE SURGICAL) on 10/17/2022. The price target of $235 was fulfilled within 8 days with a profit of $44.88 (23.61%), with a performance score of 29.51.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 29-Jun-2017
$120
$11.48 (10.58%)
$112
23 days ago
(23-Oct-2026)
23/34 (67.65%)
$16.3 (15.72%)
445
Buy Since 06-Jun-2019
$122
$13.48 (12.42%)
$112
24 days ago
(22-Oct-2026)
25/33 (75.76%)
$19.49 (19.01%)
420
Buy Since 23-Oct-2018
$118
$9.48 (8.74%)
$120
24 days ago
(22-Oct-2026)
10/14 (71.43%)
$15.49 (15.11%)
354
Buy Since 23-Jan-2017
$118
$9.48 (8.74%)
$135
24 days ago
(22-Oct-2026)
26/41 (63.41%)
$15.49 (15.11%)
336
Buy Since 02-Jun-2021
$125
$16.48 (15.19%)
$134
24 days ago
(22-Oct-2026)
8/25 (32%)
$22.49 (21.94%)
406
Which stock is Matt Miksic most bullish on?
Which stock is Matt Miksic most reserved on?
What Year was the first public recommendation made by Matt Miksic?
